Amundi Buys 23,775 Shares of ResMed Inc. (NYSE:RMD)

Amundi boosted its position in ResMed Inc. (NYSE:RMD - Free Report) by 4.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 590,212 shares of the medical equipment provider's stock after buying an additional 23,775 shares during the quarter. Amundi owned approximately 0.40% of ResMed worth $139,386,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. True Wealth Design LLC lifted its position in shares of ResMed by 2,200.0% during the 3rd quarter. True Wealth Design LLC now owns 115 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 110 shares during the last quarter. Ashton Thomas Securities LLC bought a new position in ResMed during the third quarter worth $34,000. BankPlus Trust Department acquired a new position in ResMed during the 4th quarter valued at $44,000. Rosenberg Matthew Hamilton acquired a new position in shares of ResMed during the fourth quarter valued at about $54,000. Finally, SBI Securities Co. Ltd. acquired a new stake in ResMed during the fourth quarter worth about $67,000. Institutional investors own 54.98% of the company's stock.

Insider Buying and Selling

In other ResMed news, insider Kaushik Ghoshal sold 9,745 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $239.31, for a total transaction of $2,332,075.95. Following the completion of the transaction, the insider now owns 9,725 shares in the company, valued at approximately $2,327,289.75. This represents a 50.05 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Michael J. Farrell sold 8,009 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $229.20, for a total value of $1,835,662.80. Following the completion of the sale, the chief executive officer now owns 455,472 shares in the company, valued at $104,394,182.40. The trade was a 1.73 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 38,940 shares of company stock valued at $9,164,385. 0.71% of the stock is owned by corporate insiders.

Remove Ads

ResMed Trading Down 1.7 %

NYSE:RMD traded down $3.86 during trading hours on Wednesday, hitting $221.93. The stock had a trading volume of 303,849 shares, compared to its average volume of 970,242. The business's 50 day moving average is $236.80 and its 200-day moving average is $240.13. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The company has a market cap of $32.59 billion, a price-to-earnings ratio of 26.21, a P/E/G ratio of 1.53 and a beta of 0.74. ResMed Inc. has a one year low of $172.19 and a one year high of $263.05.

ResMed (NYSE:RMD - Get Free Report) last issued its quarterly earnings data on Thursday, January 30th. The medical equipment provider reported $2.43 EPS for the quarter, topping the consensus estimate of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. Sell-side analysts anticipate that ResMed Inc. will post 9.47 EPS for the current fiscal year.

ResMed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 13th will be given a $0.53 dividend. The ex-dividend date of this dividend is Thursday, February 13th. This represents a $2.12 annualized dividend and a dividend yield of 0.96%. ResMed's dividend payout ratio is presently 25.03%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on RMD. Needham & Company LLC reiterated a "hold" rating on shares of ResMed in a research note on Friday, January 31st. KeyCorp lifted their price target on ResMed from $266.00 to $280.00 and gave the company an "overweight" rating in a report on Friday, January 31st. UBS Group raised shares of ResMed from a "hold" rating to a "strong-buy" rating in a report on Friday, January 31st. Citigroup upgraded ResMed from a "neutral" rating to a "buy" rating in a research report on Wednesday, March 5th. Finally, JPMorgan Chase & Co. boosted their target price on ResMed from $270.00 to $286.00 and gave the stock an "overweight" rating in a research report on Friday, January 31st. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $243.82.

About ResMed

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.